Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChAd63 ME-TRAP and MVA ME-TRAP with EPI Vaccines in Gambian Infants
NCT02083887Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Feb 2014
- Primary completion
- Nov 2015
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ChAd63 ME-TRAP and MVA ME-TRAP in malaria (4 arms), sponsored by University of Oxford. Primary endpoint: Safety of ChAd63 ME-TRAP / MVA ME-TRAP prime boost immunisation co-administered with EPI vaccines at 36 weeks. Started Feb 2014; status: completed.
02
Drugs
ChAd63 ME-TRAPMVA ME-TRAP
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02083887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083887.